Image-guided radiotherapy for prostate cancer: A prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages

  Wong, William W ^a   Schild, Steven E ^a   Vora, Sujay A ^a   Ezzell, Gary A ^a   Nguyen, Ba D ^a   Ram, Panol C ^a   Roarke, Michael C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Concomitant boost; External beam radiotherapy; IGRT; IMRT; ProstaScint scan; Prostate cancer

Indexed keywords

CONCOMITANT BOOST; EXTERNAL-BEAM RADIOTHERAPY; IGRT; IMRT; PROSTASCINT SCAN; PROSTATE CANCERS;

ANTIGENS; COMPUTERIZED TOMOGRAPHY; DISEASE CONTROL; PHYSICAL THERAPY; RADIOTHERAPY; TOXICITY;

DISEASES;

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HEMATURIA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL TRACT; HUMANS; INDICATORS AND REAGENTS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; UROGENITAL SYSTEM;

EID: 80255122686     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.01.048     Document Type: Article

References (21)

1. A. Jemal, R. Siegel, and J. Xu Cancer Statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
3. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
4. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
5. R.J. Ellis, E.Y. Kim, and R. Conant Radioimmunoguided imaging of prostate cancer foci with histopathological correlation Int J Radiat Oncol Biol Phys 49 2001 1281 1286 (Pubitemid 32294309)
6. R.G. Dale The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br J Radiol 58 1985 515 528 (Pubitemid 15018411)
7. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
8. M.J. Zelefsky, H. Chan, and M. Hunt Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419 (Pubitemid 44307191)
9. D. Khuntia, C.A. Reddy, and A. Mahadevan Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: What should we expect? Cancer 100 2004 1283 1292 (Pubitemid 38325958)
10. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
11. D. Kahn, R.D. Williams, and M.K. Haseman Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy J Clin Oncol 16 1998 284 289 (Pubitemid 28041610)
12. J.M. Proano, D.B. Sodee, and M.I. Resnick The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy J Urol 175 2006 1668 1672
13. S. Wilkinson, and G. Chodak The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy J Urol 172 2004 133 136 (Pubitemid 41615054)
14. S.N. Nagda, N. Mohideen, and S.S. Lo Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 834 840 (Pubitemid 46215867)
15. B.F. Koontz, V. Mouraviev, and J.L. Johnson Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 71 2008 358 361
16. R.J. Ellis, A. Vertocnik, and E. Kim Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma Int J Radiat Oncol Biol Phys 57 2003 362 370 (Pubitemid 37040931)
17. R.J. Ellis, D.A. Kaminsky, and E.H. Zhou Long-term outcomes following IGRT for localized prostate cancer: Dose escalation to SPECT/CT determined biologic target volumes and the bDFS predictive value of capromab pendetide Int J Radiat Oncol Biol Phys 75 2009 S45
18. B. Pickett, E. Vigneault, and J. Kurhanewicz Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy Int J Radiat Oncol Biol Phys 44 1999 921 929 (Pubitemid 29284143)
19. E.N. Van Lin, J.J. Futterer, and S.W. Heijmink IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI Int J Radiat Oncol Biol Phys 65 2006 291 303
20. V. Fonteyne, G. Villeirs, and B. Speleers Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion Int J Radiat Oncol Biol Phys 72 2008 799 807
21. A.K. Singh, P. Guion, and N. Sears-Crouse Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: Early results of a phase I NCI study Radiat Oncol 2 2007 36